Disc Medicine, Inc. 8-K

What Happened
Disc Medicine, Inc. (IRON) filed an 8-K dated February 27, 2026 disclosing that on February 26, 2026 its board approved and management began implementing a restructuring plan to better align the company with near-term priorities after receiving an FDA complete response letter (CRL) on February 13, 2026 for its New Drug Application (NDA) for bitopertin (for erythropoietic protoporphyria and X-linked protoporphyria). The plan reduces the workforce by approximately 20%, primarily affecting commercial and certain supporting functions, and is expected to be completed in the second quarter of 2026.

Key Details

• The restructuring was approved on February 26, 2026 and disclosed in an 8-K filed February 27, 2026.
• Workforce reduction: approximately 20%, focused on commercial and supporting functions.
• Expected charges: about $2.0 million in aggregate, primarily severance, to be recorded mainly in Q1 2026.
• Implementation timeline: underway immediately and expected to be completed in Q2 2026; costs are subject to change and additional charges may occur.

Why It Matters
For investors, this is a material operational and cost-management action tied directly to the FDA CRL for Disc’s lead program, bitopertin. The workforce cut aims to reduce near-term expenses and refocus resources, with an estimated $2.0M in one-time charges hitting results primarily in Q1 2026. The reduction in commercial staff could affect commercialization readiness and go-to-market activities if approval timelines or regulatory requirements change, so investors should monitor future updates on regulatory progress, expense trends, and any revised commercialization plans.